Background: Immune reconstitution inflammatory syndrome (IRIS) represents an unexpected inflammatory response shortly after initiation of antiretroviral therapy (ART) in some human immunodeficiency virus (HIV)-infected patients with underlying neoplasia or opportunistic infections, including tuberculosis. We hypothesized that IRIS is associated with increased glycolysis and that 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) could help identify high-risk subjects. Methods: In this prospective cohort study, 30 HIV-infected patients (CD4+ count <100 cells/µL) underwent FDG-PET/CT scans at baseline and 4-8 weeks after ART initiation. Ten patients developed IRIS (6 mycobacterial). Results: At baseline, total glycolytic activity, total lesion volume, and maximum standardized uptake values (SUVs) of pathologic FDG uptake (reflective of opportunistic disease burden) were significantly higher in IRIS vs non-IRIS (P = .010, .017, and .029, respectively) and significantly correlated with soluble inflammatory biomarkers (interferon-γ, myeloperoxidase, tumor necrosis factor, interleukin 6, soluble CD14). Baseline bone marrow (BM) and spleen FDG uptake was higher in mycobacterial IRIS specifically. After ART initiation, BM and spleen mean SUV decreased in non-IRIS (P = .004, .013) but not IRIS subjects. Our results were supported by significantly higher glucose transporter 1 (Glut-1) expression of CD4+ cells and monocytes after ART initiation in IRIS/mycobacterial IRIS compared with non-IRIS patients. Conclusions: We conclude that increased pathologic metabolic activity on FDG-PET/CT prior to ART initiation is associated with IRIS development and correlates with inflammatory biomarkers. Abnormally elevated BM and spleen metabolism is associated with mycobacterial IRIS, HIV viremia, and Glut-1 expression on CD4+ cells and monocytes. Clinical Trials Registration: NCT02147405.
Background: Immune reconstitution inflammatory syndrome (IRIS) represents an unexpected inflammatory response shortly after initiation of antiretroviral therapy (ART) in some human immunodeficiency virus (HIV)-infectedpatients with underlying neoplasia or opportunistic infections, including tuberculosis. We hypothesized that IRIS is associated with increased glycolysis and that 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) could help identify high-risk subjects. Methods: In this prospective cohort study, 30 HIV-infectedpatients (CD4+ count <100 cells/µL) underwent FDG-PET/CT scans at baseline and 4-8 weeks after ART initiation. Ten patients developed IRIS (6 mycobacterial). Results: At baseline, total glycolytic activity, total lesion volume, and maximum standardized uptake values (SUVs) of pathologic FDG uptake (reflective of opportunistic disease burden) were significantly higher in IRIS vs non-IRIS (P = .010, .017, and .029, respectively) and significantly correlated with soluble inflammatory biomarkers (interferon-γ, myeloperoxidase, tumornecrosis factor, interleukin 6, soluble CD14). Baseline bone marrow (BM) and spleen FDG uptake was higher in mycobacterial IRIS specifically. After ART initiation, BM and spleen mean SUV decreased in non-IRIS (P = .004, .013) but not IRIS subjects. Our results were supported by significantly higher glucose transporter 1 (Glut-1) expression of CD4+ cells and monocytes after ART initiation in IRIS/mycobacterial IRIS compared with non-IRIS patients. Conclusions: We conclude that increased pathologic metabolic activity on FDG-PET/CT prior to ART initiation is associated with IRIS development and correlates with inflammatory biomarkers. Abnormally elevated BM and spleen metabolism is associated with mycobacterial IRIS, HIV viremia, and Glut-1 expression on CD4+ cells and monocytes. Clinical Trials Registration: NCT02147405.
Authors: Clovis S Palmer; Joshua J Anzinger; Jingling Zhou; Maelenn Gouillou; Alan Landay; Anthony Jaworowski; Joseph M McCune; Suzanne M Crowe Journal: J Immunol Date: 2014-11-03 Impact factor: 5.422
Authors: Graeme Meintjes; Keira H Skolimowska; Katalin A Wilkinson; Kerryn Matthews; Rebecca Tadokera; Anali Conesa-Botella; Ronnett Seldon; Molebogeng X Rangaka; Kevin Rebe; Dominique J Pepper; Chelsea Morroni; Robert Colebunders; Gary Maartens; Robert J Wilkinson Journal: Am J Respir Crit Care Med Date: 2012-06-14 Impact factor: 21.405
Authors: Cari Stek; Charlotte Schutz; Lisette Blumenthal; Friedrich Thienemann; Jozefien Buyze; Christiana Nöstlinger; Raffaella Ravinetto; Edwin Wouters; Robert Colebunders; Gary Maartens; Robert J Wilkinson; Lutgarde Lynen; Graeme Meintjes Journal: JMIR Res Protoc Date: 2016-08-29
Authors: Hanif Esmail; Rachel P Lai; Maia Lesosky; Katalin A Wilkinson; Christine M Graham; Anna K Coussens; Tolu Oni; James M Warwick; Qonita Said-Hartley; Coenraad F Koegelenberg; Gerhard Walzl; JoAnne L Flynn; Douglas B Young; Clifton E Barry Iii; Anne O'Garra; Robert J Wilkinson Journal: Nat Med Date: 2016-09-05 Impact factor: 53.440
Authors: Lanbo Shi; Hugh Salamon; Eliseo A Eugenin; Richard Pine; Andrea Cooper; Maria L Gennaro Journal: Sci Rep Date: 2015-12-10 Impact factor: 4.379
Authors: Maura Manion; Augusto Dulanto Chiang; Luxin Pei; Chun-Shu Wong; Pavel Khil; Dima A Hammoud; Megan Anderson; Elizabeth Laidlaw; Safia Kuriakose; Andrea Lisco; Adrian M Zelazny; John P Dekker; Irini Sereti Journal: J Infect Dis Date: 2021-08-02 Impact factor: 5.226
Authors: Zeping Wang; Maura M Manion; Elizabeth Laidlaw; Adam Rupert; Chuen-Yen Lau; Bryan R Smith; Avindra Nath; Irini Sereti; Dima A Hammoud Journal: AIDS Date: 2021-07-01 Impact factor: 4.632
Authors: Luxin Pei; Kiyoshi F Fukutani; Rafael Tibúrcio; Adam Rupert; Eric W Dahlstrom; Frances Galindo; Elizabeth Laidlaw; Andrea Lisco; Maura Manion; Bruno B Andrade; Irini Sereti Journal: Front Immunol Date: 2021-06-15 Impact factor: 7.561